Addressing Representative Gaps in Clinical Research

• Women, older adults, and marginalized groups are historically underrepresented in clinical trials, limiting the medical evidence available for their care.
• Current practices often rely on data from "typical" patients who do not reflect the diversity of those living with chronic conditions.
• The EU-funded READI project aims to dismantle barriers to participation, ensuring that future clinical research is inclusive and representative of real-world patient populations.

The Clinical Representation Gap

• Gender bias: Heart disease has long been viewed as a "male" problem, leading to male-focused studies and lower awareness of feminine-presenting heart attack symptoms like nausea and extreme fatigue.
• Age bias: Trials frequently exclude patients over 75, despite them being the primary demographic for many conditions, resulting in medication data that may lack safety and efficacy profiles for elderly populations.
• Structural barriers: Inaccessible trial locations, complex study information, and lack of accommodation for working or caregiving responsibilities contribute to ongoing exclusion.

The READI Project Approach

• Collaboration: The initiative works with 88 partners across 20 countries, supported by the Innovative Health Initiative (IHI) under the EU’s Horizon Europe programme.
• Inclusive Design: The project is auditing the entire research process, from study design and recruitment to patient support during trials.
• Community Engagement: Leveraging family doctors to identify potential participants and creating a digital platform to provide clearer information about the value and process of clinical studies.

Evolving Standards

• Mindset Shift: Researchers, pharmaceutical companies, and regulators are increasingly prioritizing inclusion to prevent unexpected adverse events that occur when under-represented populations finally receive new drugs.
• Risk Assessment: Rather than excluding groups due to perceived risk, the new focus is on establishing appropriate safeguards and treating inclusion as a starting point for scientific integrity.
• Long-term Goal: To generate robust medical evidence that accurately reflects the diversity of real-world patients, ultimately improving health outcomes for everyone.